Premium
Statin use and delayed onset of Huntington's disease
Author(s) -
Schultz Jordan L.,
Nopoulos Peg C.,
Killoran Annie,
Kamholz John A.
Publication year - 2019
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.27591
Subject(s) - statin , medicine , hazard ratio , proportional hazards model , disease , physical therapy , confidence interval
Background There is evidence to suggest that 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitors (statins) may be beneficial in Huntington's disease (HD). Objective This study aimed to determine if statin use was associated with delayed motor diagnosis in participants with premotor HD. Methods Among premotor HD participants from the Enroll‐HD database, statin users were propensity score matched with statin nonusers based on cytosine‐adenine‐guanine–age product score, cytosine‐adenine‐guanine repeat length, baseline age, sex, and region. A Cox regression survival analysis compared the annualized hazard ratio (HR) of receiving a motor diagnosis between the 2 groups. Results The annualized HR of progressing to an HD motor diagnosis was lower in the statin users (n = 89) when compared with the statin nonusers (n = 89; HR = 0.27 [95% CI 0.18‐0.50], P < .0001). Conclusions In patients with premotor HD, statin use was associated with a delayed motor diagnosis of HD. Further studies are warranted to investigate if statins would be an effective disease‐modifying therapy for HD. © 2018 International Parkinson and Movement Disorder Society